Stop TB Partnership

TB REACH - Results

TB REACH Wave 1 Results

TB REACH collects case finding data quarterly from all of its grantees and has an independent agency that is tasked with monitoring and evaluating progress of all projects.

Preliminary analysis shows that for the Wave 1 TB REACH projects, in the first 12 months of project implementation, project areas delivered an average of 33% increase in case detection compared while some projects have seen increases of 60% to over 100%. In human terms, this translates into an additional 14,929 people so far that would otherwise have continued to infect others - many of whom would have died.

Cost: Through September, 2011, 22 projects have spent $12.5 million with some reaching additional cases for as low as $70. The projects are covering a population of about 65 million people. Average spent per capita of population covered per year is 0.19 USD.

Note: Preliminary data from 27 of 30 projects.

TB REACH Wave 3 has begun

TB REACH supports global roll-out of Xpert MTB/RIF

TB REACH is supporting 33 projects implementing Xpert MTB/RIF in 18 countries, many for the first time in the country. In total, TB REACH grantees will be putting almost 150 GeneXpert instruments into service and testing over 200,000 TB suspects in the coming months. Projects have placed instruments in a variety of settings, including remote, rural areas, on mobile units, in private laboratories, reference laboratories and primary health facilities; and supplemented it by innovative case finding activities to improve access particularly to vulnerable and high risk population groups. Early results from the projects show a wide variety of experiences with the machine when put to use. In Tanzania the innovative approach of case finding along with the implementation of this new diagnostic test has helped increase TB case detection in the project area by 40% over the previous year. In Pakistan project areas in Karachi, TB positivity rates using Xpert MTB/RIF have been close to 20% even when testing among smear negative suspects. Procurement of equipment has been fast as a result of pooled procurement undertaken by the TB REACH Secretariat via the Global Drug Facility's mechanisms.